Review Papers Claim by Claim

Visual Review — Nanomedicine in Cancer Therapy (Pagar et al., DOI:10.71097/ijsat.v16.i1.3138)

Data-first, visuals-first critique: figures below reproduce key design parameters reported in the paper and then unpack strengths, blindspots, and actionable next steps. All claims are sourced to the review text.

Pagar et al. 2025 — review

Key design parameters (reported values)

Source for plotted numbers: ranges and specific values are reported directly in the review (optimal nanoparticle size 10–200 nm; tumor pH ≈6.5–6.8; intracellular GSH in tumors ~2–10 mM vs ~2–10 µM in normal tissues; tumor temperature 40–42°C) Design parameters from review

Clinical / near‑clinical examples cited

The review calls out clinically used liposomal formulations (Doxil®, DaunoXome®) as examples where nanocarrier platforms reached practice; the review draws lessons but does not supply new clinical data Clinical liposome examples

Paper strengths vs limitations (author‑level synthesis)

These qualitative scores are derived from the review's scope (wide topics), clinical examples, but limited primary-data depth and lack of explicit, reproducible methods for literature selection Scope and methods

Critical analysis — concise, evidence‑anchored

1. What the paper does well: clear taxonomy of carrier classes (liposomes, polymeric NPs, dendrimers, metallic and carbon-based NPs), mechanisms of passive/active/stimuli targeting, and concrete translational hurdles (biocompatibility, scale‑up, regulatory gaps) Paper strengths list
2. Primary limitation: narrative (non-systematic) review methodology — no reproducible search strategy, inclusion/exclusion criteria, or data extraction tables are provided; this raises selection and publication‑bias risks and limits reproducibility Methodologic limitation
3. Evidence framing & overreach risks: the review correctly reports preclinical potential (e.g., stimuli‑responsive carriers) but does not always distinguish preclinical (in vitro/in vivo) evidence strength from clinical-level evidence — careful readers must not conflate promising mechanisms with proven clinical benefit Preclinical vs clinical distinction
4. Missing or under‑emphasized items: (a) systematic assessment of failed/null clinical studies (publication bias); (b) biodistribution and long‑term organ accumulation quantitative summaries; (c) regulatory pathway specifics (FDA/EMA guidance variance) and manufacturing reproducibility metrics; (d) patient heterogeneity effects on EPR — these blindspots weaken clinical translation guidance Blindspots and missing items
5. Practical value: high for newcomers and for those seeking a taxonomy of approaches and design parameters; moderate for translational decision‑making because the review lacks systematic evidence-weighting and raw data that would support go/no‑go decisions in development programs Utility assessment

Recommendations for authors / future reviews

• Adopt systematic review methods (PRISMA) or at least a reproducible search strategy and include a table of included/excluded studies and levels of evidence.
• Provide quantitative summaries (tables/forest-plots) that separate preclinical vs clinical outcomes, and report organ biodistribution & long‑term accumulation data where available.
• Explicitly list negative or null clinical trials and reasons for clinical failure to counter publication bias.
• Where possible, include standard metrics (size, PDI, zeta, encapsulation efficiency, in vivo %ID/g) for referenced formulations to aid reproducibility comparisons.

Author reviews